AbbVie Inc. (ABBV) stock analysis

On Oct 15, 2026, our model rated AbbVie Inc. (ABBV) BUY with 51% confidence at a price of $283.48. That means most of the technical, fundamental, money-flow and news signals point to upside.

Technical picture

The 14-day RSI is 70, showing healthy upward momentum without being stretched.

MACD is above its signal line, a sign that short-term momentum is turning up.

The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.

Volume is about normal (1.2x the 20-day average).

Trend structure and money flow

Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.

The most recent swing high is $233.76 and the swing low is $189.40; traders often treat these as resistance and support.

Price is sitting in a bullish order block, a zone where large buyers stepped in before.

Fundamentals

The PEG ratio is 0.58, which looks cheap relative to its expected growth.

The company reports a profit margin of 9.8% and revenue growth of +10.2%.

In its latest quarter it earned $3.65 per share, which beat the $3.61 analysts expected, with revenue +10.2% year over year.

Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $282.61.

The next earnings report is expected around Oct 30, 2026; prices often move sharply around earnings.

Trade plan from the model

The model's long / bullish plan uses an entry near $288.57, a target of $314.76 (+9.1%) and a stop-loss at $274.78 (-4.8%).

That is a reward-to-risk ratio of about 1.9 to 1: the potential gain is larger than the potential loss.

The plan has a time limit: reassess by Oct 29, 2026 whatever the price does.

The model's one-paragraph read

Leans BUY — composite score +0.51 (BUY). Technicals: RSI 69.9, MACD bullish, price above SMA50. Fundamentals: PEG 0.58, margin 9.8%, revenue growth 10.2%. Financial results: YoY revenue +10.2%, last EPS surprise +1.1%, next earnings 2026-10-30. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: neutral. Memory: 2 prior look(s); 100% of directional calls matched later price. Suggested levels: entry $288.57, target $314.76, stop-loss $274.78, exit by 2026-10-29 (exit before next earnings (2026-10-30) -- this signal doesn't price in that report).

Past ratings for ABBV

"Move since" compares each call's price with the latest analysed price.

Recent news on ABBV

• Oct 15, 2026: Where Could Johnson & Johnson's Next Growth Come From? (Trefis)
• Oct 13, 2026: AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease (PR Newswire)

Search all news on ABBV →

Other Healthcare stocks we cover

ALC · AMGN · AMRX · ANIP · ARWR · ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY

Frequently asked questions

Is ABBV a buy right now?

As of Oct 15, 2026, our automated model rates AbbVie Inc. (ABBV) BUY with 51% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.

What is the price target for ABBV?

The model's most recent plan targets $314.76 with a stop-loss at $274.78, from an entry near $288.57.

When does AbbVie Inc. report earnings next?

The next earnings report is expected around Oct 30, 2026.

What does a BUY rating mean?

A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.